A number of other brokerages have also recently weighed in on MOR. Berenberg Bank set a €68.00 ($80.95) price objective on shares of MorphoSys AG and gave the stock a buy rating in a research note on Thursday, May 25th. Independent Research GmbH set a €77.00 ($91.67) price objective on shares of MorphoSys AG and gave the stock a buy rating in a research note on Monday, August 7th. Commerzbank Ag set a €76.00 ($90.48) target price on shares of MorphoSys AG and gave the stock a buy rating in a research report on Tuesday, June 6th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) target price on shares of MorphoSys AG and gave the stock a neutral rating in a research report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of €70.38 ($83.78).
MorphoSys AG (ETR MOR) opened at 65.25 on Thursday. MorphoSys AG has a one year low of €35.72 and a one year high of €70.90. The firm’s 50-day moving average is €60.15 and its 200 day moving average is €59.03. The firm’s market capitalization is €1.89 billion.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.